Altimmune (ALT) Operating Income (2016 - 2025)
Historic Operating Income for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to -$20.9 million.
- Altimmune's Operating Income rose 1577.91% to -$20.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.5 million, marking a year-over-year increase of 1917.91%. This contributed to the annual value of -$103.2 million for FY2024, which is 755.04% down from last year.
- Altimmune's Operating Income amounted to -$20.9 million in Q3 2025, which was up 1577.91% from -$22.9 million recorded in Q2 2025.
- Over the past 5 years, Altimmune's Operating Income peaked at -$14.9 million during Q1 2021, and registered a low of -$33.6 million during Q4 2023.
- In the last 5 years, Altimmune's Operating Income had a median value of -$23.1 million in 2022 and averaged -$23.7 million.
- Per our database at Business Quant, Altimmune's Operating Income plummeted by 12312.05% in 2021 and then surged by 2604.47% in 2024.
- Over the past 5 years, Altimmune's Operating Income (Quarter) stood at -$24.0 million in 2021, then increased by 3.71% to -$23.1 million in 2022, then tumbled by 45.59% to -$33.6 million in 2023, then increased by 26.04% to -$24.9 million in 2024, then grew by 16.11% to -$20.9 million in 2025.
- Its last three reported values are -$20.9 million in Q3 2025, -$22.9 million for Q2 2025, and -$21.8 million during Q1 2025.